BIOHEART-B (02185) surged over 15% intraday, following yesterday's closing gain of more than 50%. As of press time, the stock was up 11.4% to HK$10.36, with trading volume reaching HK$42.644 million.

On the news front, the American Heart Association (AHA), American College of Cardiology (ACC), and other institutions recently jointly released updated guidelines for the prevention, detection, evaluation, and management of high blood pressure in adults, representing significant revisions to the 2017 guidelines. The new guidelines include updates in hypertension diagnosis, risk assessment, and treatment approaches, aimed at providing more precise clinical guidance and reducing cardiovascular disease (CVD) risk. Notably, renal denervation (RDN) has been added as a newly recommended treatment option.

Additionally, it's worth noting that the Centers for Medicare & Medicaid Services (CMS) previously released a new Medicare coverage proposal for RDN. The new proposal suggests including RDN in Medicare coverage for patients with uncontrolled hypertension. The proposal has initiated a 30-day public comment period, with the final decision expected to be announced on or before October 8, 2025.